Effects of ezetimibe on glucose metabolism in patients with type 2 diabetes: A 12-week, open-label, uncontrolled, pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 71, Issue 4, 2010, Pages 252-258

  Nozue, Tsuyoshi ^a   Michishita, Ichiro ^a   Mizuguchi, Ichiro ^a  

^a YOKOHAMA SAKAE KYOSAI HOSPITAL   (Japan)

Author keywords

Cholesterol; Ezetimibe; RLP C; Type 2 diabetes mellitus

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; C REACTIVE PROTEIN; EZETIMIBE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; SULFONYLUREA;

AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; DIET; DRUG EFFICACY; DYSLIPIDEMIA; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INTERVIEW; JAPANESE; LABORATORY TEST; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

EID: 77958529681     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2010.08.002     Document Type: Article

References (18)

1. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol. 2000, 129:1748-1754.
2. van Heek M, Farley C, Compton DS, et al. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol. 2001, 134:409-417.
3. Altmann SW, Davis HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science. 2004, 303:1201-1204.
4. Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002, 90:1092-1097. Ezetimibe Study Group, [published correction appears in Am J Cardiol. 2003;91:1399].
5. Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: A pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003, 57:363-368. Ezetimibe Study Group.
6. Deushi M, Nomura M, Kawakami A, et al. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett. 2007, 581:5664-5670.
7. Masuda D, Nakagawa-Toyama Y, Nakatani K, et al. Ezetimibe improves postprandial hyperlipidaemia in patients with type lib hyperlipidaemia. Eur J Clin Invest. 2009, 39:689-698.
8. Shimano H, Arai H, Harada-Shiba M, et al. Proposed guidelines for hypertriglyceridemia in Japan with non-HDL cholesterol as the second target. J Atheroscler Thromb. 2008, 15:116-121.
9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997, 20:1183-1197.
10. Nozue T, Michishita I, Mizuguchi I Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb. 2010, 17:37-44.
11. Boden G, Laakso M Lipids and glucose in type 2 diabetes: What is the cause and effect?. Diabetes Care. 2004, 27:2253-2259.
12. Bajaj M, Suraamornkul S, Kashyap S, et al. Sustained reduction in plasma free fatty acid concentration improves insulin action without altering plasma adipocytokine levels in subjects with strong family history of type 2 diabetes. J Clin Endocrinol Metab. 2004, 89:4649-4655.
13. Davis HR, Zhu LJ, Hoos LM, et al. Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J Biol Chem. 2004, 279:33586-33592.
14. Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick Cl-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007, 117:1968-1978.
15. Browning JD, Horton JD Molecular mediators of hepatic steatosis and liver injury. J Clin Invest. 2004, 114:147-152.
16. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008, 359:1343-1356. SEAS Investigators.
17. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005, 366:1267-1278. Cholesterol Treatment Trialists' (CTT) Collaborators, [published corrections appear in Lancet. 2008;371:2084 and Lancet. 2005;366:1358].
18. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008, 359:1357-1366.